| Ytd | 5.90% | |
| 1y | 43.63% |
| Open | 48.02 | Prev Close | 49.02 | Low | 45.88 | High | 48.52 | Mkt Cap | 5.68B |
| Vol | 3.25M | Avg Vol | 1.49M | EPS | -3.31 | P/E | N/A | Forward P/E | -18.26 |
| Beta | 0.68 | Short Ratio | 17.04 | Inst. Own | 117.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 53.10 | 200-d Avg | 48.20 | 1yr Est | 69.94 |
SRRK News
Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SR
Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD
Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outpe
Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overwei
Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the p
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mix
Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform
Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM En
Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Eq
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold move
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SM
Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform a
Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise
The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Ro
FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor
Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved sp
Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the compa
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premark
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)
Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pendi
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:
BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK)
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prep
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA deci
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that t
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and
Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping th
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)
Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its appli
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part o
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains
Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the ana
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)
Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) w